About Us

Pipeline

Press Releases

Location

About Us

  • About Us

  • History

History

Overview

Company Name J INTS BIO CO., LTD.
CEO Anna Jo, Choonok Kim
Date of
Establishment		 Mar 04, 2020
Business Areas Research and Development of novel anticancer and orphan drugs
Headquarters #311~313, 49 Achasan-ro 17-gil, Seongdong-gu, Seoul, Korea

Research Institute

Corporate Research Institute, Korea

  • Date of Establishment April 12, 2021
  • Address #526, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Korea

R&D Center, Singapore

  • Date of Establishment June 24, 2021
  • Address 13A MACKENZIE ROAD SINGAPORE

AI Drug Discovery Research Institute, Korea

  • Date of Establishment January 2, 2024
  • Address Core Protein Resources Service Center R2, Daegu Gyeongbuk Institute of Science and Technology (DGIST), 333, Techno jungang-daero, Hyeonpung-eup, Dalseong-gun, Daegu, Korea

History

2025
2025.04~
  • JIN-A02 – Poster Presentation of Phase 1/2 Clinical Trial at ASCO
  • JIN-A02 – Poster Presentation of Phase 1/2 Clinical Trial at AACR
  • JIN-001 – Poster Presentation of Preclinical Study at AACR
2024
2024.12
  • 2024 Korea Value Management Award
  • 5-Year Consecutive Winner in Bio Sector – Korea Excellent Company Awards
2024.04~10
  • JIN-A02 – Poster Presentation of Phase 1/2 Clinical Trial at AACR
  • JIN-A02 – Poster Presentation of Phase 1/2 Clinical Trial at ASCO
  • JIN-A02 – Poster Presentation of Phase 1/2 Clinical Trial at WCLC
  • JIN-A02 – Poster Presentation of Phase 1/2 Clinical Trial at ENA
  • JIN-001 – Poster Presentation of Preclinical Study at ENA
2024.02
  • Ministry of Health and Welfare Award (Bio Research Category),
    Best Brand in Bio Research Category
2023
2023.12
  • 4-Year Consecutive Winner in Bio Sector – Korea Excellent Company Awards
2023.08
  • JIN-A02 - Submission of Orphan Drug Designation Application to the US FDA
2023.07
  • JIN-A02 – First Patient Enrollment in Phase 1 Clinical Trial
2023.05
  • JIN-A04 – Technology Transfer to Yuhan
  • JIN-A02 - TFDA IND Approval
2023.04~12
  • JIN-A04 - Poster Presentation of Preclinical Study Results at AACR
  • JIN-A04 - Poster Presentation of Preclinical Study Results at WCLC
  • JIN-A02 - Poster Presentation of Phase 1/2 Clinical Trial at ESMO ASIA
2023.03
  • JIN-A02 - MFDS IND Approval
2022
2022.11
  • JIN-A02 - FDA IND Approval (Approved in approximately 1 Year from Candidate Stage)
2022.08~11
  • JIN-001 - Poster Presentation of Preclinical Study Results at SNO
  • JIN-A02 - European Thoracic Oncology (ETOP) Selection
  • JIN-A02 - Poster Presentation of Preclinical Study Results at ESMO
  • JIN-A02 - Oral Presentation of non-clinical Study at WCLC
  • JIN-A02 - Advisory Meeting with Non-Small Cell Lung Cancer Experts (International)
2022.06~09
  • Quality Management System (ISO 9001) Certification
  • Anti-Bribery Management System (ISO 37001) Certification
  • Compliance Management System (ISO 37301) Certification
2021
2021.08~2022.04
  • JIN-A02 - Advisory Meeting with Non-Small Cell Lung Cancer Experts (Korea)
2021.08
  • Technology Transfer of Lead and Candidate Compounds for Lung Cancer Treatment
    (Korea Research Institute of Chemical Technology, Yonsei University Health System)